NASDAQ: GCTKGlucotrack Inc Stock
$0.50+0.01 (+2.04%)
Updated May 17, 2024
GCTK Price
$0.50
Fair Value Price
$0.21
Market Cap
$13.70M
52 Week Low
$0.13
52 Week High
$0.99
P/E
-1.22x
P/B
36.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
4.6
Operating Cash Flow
-$8M
Beta
0.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GCTK Overview
GlucoTrack, Inc., a medical device company, develops non-invasive glucose monitoring devices for people suffering from diabetes and pre-diabetics. Known as Integrity Applications, Inc. until 2021/11, GlucoTrack was founded in 2001 and is based in Or Yehuda, Israel.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GCTK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GCTK ($0.50) is overvalued by 141.62% relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GCTK ($0.50) is not significantly undervalued (141.62%) relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GCTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GCTK due diligence checks available for Premium users.
Be the first to know about important GCTK news, forecast changes, insider trades & much more!
GCTK News
Valuation
GCTK fair value
Fair Value of GCTK stock based on Discounted Cash Flow (DCF)
Price
$0.50
Fair Value
$0.21
Overvalued by
141.62%
GCTK ($0.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GCTK ($0.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GCTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GCTK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.22x
Industry
59.83x
Market
30.97x
GCTK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
36.43x
Industry
3.64x
GCTK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GCTK's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.9M
Profit Margin
0%
GCTK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.1M
Liabilities
$1.7M
Debt to equity
4.6
GCTK's short-term assets ($1.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GCTK's short-term assets ($1.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GCTK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GCTK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$59.0k
Financing
$0.0
GCTK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GCTK vs Medical Stocks
Glucotrack Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.